Caris Life Sciences, Inc. (CAI) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 8 (last 6 releases) |
Last 6 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | after close | 36 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | after close | 43 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, November 04, 2026 — Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial result" exhibit |
| Q3 FY2026 | "The decrease was driven by continued investment in commercial expansion and marketing expenditures, inventory build-up for new solution launches, and research and development efforts. 2026 Financial Outlook and Guidance Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025." exhibit |
| Q3 FY2026 | "Conference Call Information Event: Caris Third Quarter 2026 Financial Results Conference Call Date: Wednesday, November 4, 2026 Time: 3:30 p.m. CT (4:30 p.m. ET) Webcast Link: https://edge.media-server.com/mmc/p/nri9afky Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28% IRVING, Texas, August 05, 2026 — Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions t" exhibit |
| Q2 FY2026 | "The improvement was driven by improved total clinical case volume and ASP improvements. 2026 Financial Outlook and Guidance Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.03 billion to $1.04 billion, representing growth of 27% to 28% compared to full year 2025 and reaffirms its guidance to clinical therapy selection volume growth of approximately 20% compared to full year 2025." exhibit |
| Q2 FY2026 | "Conference Call Information Event: Caris Second Quarter 2026 Financial Results Conference Call Date: Wednesday, August 5, 2026 Time: 3:30 p.m. CT (4:30 p.m. ET) Webcast Link: https://edge.media-server.com/mmc/p/ff8xb4qs Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CAI
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CAI
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CAI/"><img src="https://veritasdata.dev/embed/CAI.svg" alt="CAI earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CAI/)
Script
<script async src="https://veritasdata.dev/embed/CAI.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CAI"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.